Patient characteristics
| Patient characteristics . | Treatment naive at enrollment . | Relapsed at enrollment . |
|---|---|---|
| Sample size (N = 255 patients), n (%) | 198 (78) | 57 (22) |
| Age, y | ||
| Median | 61 | 63 |
| Range | 35-96 | 46-82 |
| Sex | ||
| Female, n (%) | 71 (36) | 14 (25) |
| Male, n (%) | 127 (64) | 43 (75) |
| Rai stage | ||
| Low (0), n (%) | 91 (46) | 10 (17) |
| Intermediate (I-II), n (%) | 98 (49) | 30 (53) |
| High (III-IV), n (%) | 9 (5) | 17 (30) |
| Median time from diagnosis to enrollment, mo | ||
| Median | 7 | 76 |
| Range | 0-306 | 5-244 |
| Median time from enrollment to analysis, mo | ||
| Median | 51 | 44 |
| Range | 14-69 | 14-69 |
| IgVH mutational status | ||
| Unmutated (≥ 98% homology to germ line), n (%) | 82 (41) | 34 (60) |
| Mutated (< 98% homology to germ line), n (%) | 108 (55) | 20 (35) |
| Not evaluable, n (%) | 8 (4) | 3 (5) |
| Prioritized interphase FISH | ||
| 17p deletion, n (%) | 17 (9) | 9 (16) |
| 11q deletion, n (%) | 18 (9) | 12 (21) |
| 12 trisomy, n (%) | 26 (13) | 10 (17) |
| Normal karyotype, n (%) | 43 (22) | 9 (16) |
| 13q deletion (sole abnormality), n (%) | 90 (45) | 16 (28) |
| FISH data not available, n (%) | 4 (2) | 1 (2) |
| Prioritized interphase FISH-25* | ||
| 17p deletion, n (%) | 16 (8) | 9 (16) |
| 11q deletion, n (%) | 14 (7) | 10 (17) |
| 12 trisomy, n (%) | 24 (12) | 9 (16) |
| Normal karyotype, n (%) | 61 (31) | 9 (16) |
| 13q deletion (sole abnormality), n (%) | 79 (40) | 19 (33) |
| FISH data not available, n (%) | 4 (2) | 1 (2) |
| ZAP70 expression | ||
| Negative (≤ 20%), n (%) | 116 (59) | 19 (33) |
| Positive (> 20%), n (%) | 82 (41) | 38 (67) |
| TP53 exon 2-10 mutations | ||
| Wild-type, n (%) | 174 (88) | 45 (79) |
| Mutated, n (%) | 24 (12) | 12 (21) |
| Number of prior therapies | ||
| Median | NA | 1 |
| Range | NA | 1-7 |
| Patient characteristics . | Treatment naive at enrollment . | Relapsed at enrollment . |
|---|---|---|
| Sample size (N = 255 patients), n (%) | 198 (78) | 57 (22) |
| Age, y | ||
| Median | 61 | 63 |
| Range | 35-96 | 46-82 |
| Sex | ||
| Female, n (%) | 71 (36) | 14 (25) |
| Male, n (%) | 127 (64) | 43 (75) |
| Rai stage | ||
| Low (0), n (%) | 91 (46) | 10 (17) |
| Intermediate (I-II), n (%) | 98 (49) | 30 (53) |
| High (III-IV), n (%) | 9 (5) | 17 (30) |
| Median time from diagnosis to enrollment, mo | ||
| Median | 7 | 76 |
| Range | 0-306 | 5-244 |
| Median time from enrollment to analysis, mo | ||
| Median | 51 | 44 |
| Range | 14-69 | 14-69 |
| IgVH mutational status | ||
| Unmutated (≥ 98% homology to germ line), n (%) | 82 (41) | 34 (60) |
| Mutated (< 98% homology to germ line), n (%) | 108 (55) | 20 (35) |
| Not evaluable, n (%) | 8 (4) | 3 (5) |
| Prioritized interphase FISH | ||
| 17p deletion, n (%) | 17 (9) | 9 (16) |
| 11q deletion, n (%) | 18 (9) | 12 (21) |
| 12 trisomy, n (%) | 26 (13) | 10 (17) |
| Normal karyotype, n (%) | 43 (22) | 9 (16) |
| 13q deletion (sole abnormality), n (%) | 90 (45) | 16 (28) |
| FISH data not available, n (%) | 4 (2) | 1 (2) |
| Prioritized interphase FISH-25* | ||
| 17p deletion, n (%) | 16 (8) | 9 (16) |
| 11q deletion, n (%) | 14 (7) | 10 (17) |
| 12 trisomy, n (%) | 24 (12) | 9 (16) |
| Normal karyotype, n (%) | 61 (31) | 9 (16) |
| 13q deletion (sole abnormality), n (%) | 79 (40) | 19 (33) |
| FISH data not available, n (%) | 4 (2) | 1 (2) |
| ZAP70 expression | ||
| Negative (≤ 20%), n (%) | 116 (59) | 19 (33) |
| Positive (> 20%), n (%) | 82 (41) | 38 (67) |
| TP53 exon 2-10 mutations | ||
| Wild-type, n (%) | 174 (88) | 45 (79) |
| Mutated, n (%) | 24 (12) | 12 (21) |
| Number of prior therapies | ||
| Median | NA | 1 |
| Range | NA | 1-7 |
FISH findings in ≥ 25% of nuclei.